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ABSTRACT
Antibiotic prescriptions for lower respiratory tract infections occur commonly in primary care but
there is uncertainty about the most effective initial treatment strategy. Both increasing antimi-
crobial resistance and awareness of preventable harm from medicines make resolving this
uncertainty a priority. Pragmatic, real-life epidemiological investigations are needed to inform
future interventional studies.
In this cross-sectional database study we analysed antibiotic prescriptions for non-pneumonic,
lower respiratory tract infections (LRTI) in primary care as captured in the Optimum Care
Database from 1984 to 2017. The primary outcome was a second antibiotic prescription for a
LRTI code within 14 days of index prescription, the secondary outcome further antibiotic pre-
scription for any indication. Only individuals without chronic respiratory diseases were included.
We conducted univariable analysis to identify factors associated with repeat prescriptions and
generate hypotheses for forthcoming projects.
We analysed 367,188 index prescriptions for LRTI. Amoxicillin was the commonest used index
drug (65.1%). In 6% a second antibiotic course coded for a further LRTI was prescribed (11.2%without
this coding restriction). Further antibiotic prescriptions for LRTI were significantly associated with
older age, previous smoking, seven day index courses and not using amoxicillin initially. The largest
effect size was seenwhen amoxicillin was not used as index drug (odds ratio (OR) 1.15, p < 0.001). This
would support current prescribing practice for amoxicillin as index drug in those without respiratory
disease. Prospective studies are needed to explore the observed differences.
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Introduction
Lower respiratory tract infections (LRTI) are the com-
monest reason for antibiotic prescriptions in primary
care across Europe and the probability of antibiotic
prescription for coughs and colds by general practi-
tioners in the United Kingdom (UK) increased by 40
% between 1999 and 2011 [1,2]. It is presumed that
there are variations in prescribing practice but unclear
whether these result in different patient outcomes.
Primary care is an ideal target for optimising antibiotic
therapy since 74% of all UK antibiotics are prescribed
here [3]. The risks of rising antimicrobial resistance and
adverse effects, including infective diarrhoea, must be
balanced with treatment failure [4–7].
Since real-life experiences should inform real-life
decision making, we undertook this retrospective obser-
vational investigation of antibiotic prescriptions in
non-pneumonic LRTI and their outcomes from 1984
to 2017. We described prescribing practice and investi-
gated factors associated with repeat prescriptions with
the aim to identify areas for further investigations.
Methods
We carried out a cross-sectional database study drawing
on retrospective, electronic medical records from the
Optimum Patient Care Research Database (OPCRD).
We included all subjects older than 15 years who
received at least one antibiotic prescription for LRTI
from 27 April 1984 to 5 January 2017. Primary outcome
was a new antibiotic prescription for a LRTI READ code
within 14 days of initial prescription. Secondary out-
come was an antibiotic prescription for any indication
within 14 days of index prescription. We excluded cases
with coded diagnoses of pneumonia, chronic respiratory
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conditions (e.g. asthma, chronic obstructive pulmonary
disease (COPD)) and those whose index antibiotic
course was longer than 28 days.
The OPCRD comprised data extracted through the
Optimum Patient Care (OPC) Clinical Service Evaluation
(http://optimumpatientcare.org/opcrd/). The OPCRD is a
research-quality primary care database with a focus on
respiratory diseases. It contained anonymised, routinely
recorded patient data from over 525 UK general practices.
The OPCRD was approved by the Trent Multi-Centre
Research Ethics Committee for clinical research use. The
study protocol was approved by the OPCRD’s
Anonymised Data Ethics Protocols and Transparency
Committee.
Data was analysed using SPSS version 22 (IBM).
Univariable analysis was carried out for gender, age,
body mass index (BMI), smoking status, index antibio-
tic drug and index duration. Statistically significant
results were defined as p < 0.05, 95% confidence inter-
vals were given where appropriate. Summary statistics,
odds ratios, Chi-squared and student T-tests were pre-
sented as appropriate for each variable based on type
and distribution of data. Subgroup analysis was carried
out for cases with more than one index prescription
and cases from 1 January 2011 to 5 January 2017 to
establish if the observed effects were maintained in
current antibiotic prescribing practice.
Results
There were 1,549,402 antibiotic prescriptions in the
OPCRD from 1984 to 2017; of these 753,885 were for
‘simple’ LRTI (i.e. no underlying asthma, COPD or
other chronic lung disease) in patients over 15 years.
‘Chest infection not otherwise specified’, ‘bronchitis’
and ‘lower respiratory tract infections’ were the com-
monest codes for LRTI (67.5%, 21.7%, 10.2% respec-
tively). We analysed the 367,188 cases (51%) for which
an index duration was clearly documented (see supple-
mentary figure).
Of the total eligible 367,188 index prescriptions,
58.9% occurred in female patients. Mean age was
55.4 years, range 16–106 years. Mean BMI was
28.1 ± 6.1 (standard deviation, SD). 35.4% were
non-smokers, 27% current smokers and 28.9% were
ex-smokers (missing smoking status in 8.7%). Most
prescriptions occurred from 2006 to 2010 (35.3%).
Most patients received only one index prescription
(59.3%), with 20.4% having two and 20.3% three or
more separate index prescriptions. The commonest
index duration was 7 days (74.1%), followed by 5 or
6 days (22.7%). Amoxicillin was the index antibiotic
prescribed most frequently (65.1%), clarithromycin and
erythromycin were the next most frequent (9.1% and
7.4% respectively). About 548 cases received 2 further
antibiotic courses within 14 days of the index prescrip-
tion – these were excluded from further analysis.
Further antibiotic prescriptions for LRTI
41,227 cases had a second antibiotic prescription
within 14 days of the index prescription (11.2%).
More than half of the additional antibiotic prescrip-
tions were coded for another LRTI (54.8%, 22,176 of
41,227). Most of the 22,176 s prescriptions for another
LRTI code were for 7 days (75.2%). Clarithromycin,
amoxicillin and doxycyline were the most commonly
used second line antibiotics (23.3%, 15.5% and 15.1%
respectively).
Those receiving further antibiotics for LRTI were
significantly older (mean 57.5 versus 54.1 years, mean
difference −3.4 (MD), 95% CI −3.6 – −3.1, p < 0.001)
than those not receiving antibiotics (see Table 1).
Current smokers had a significantly reduced risk of
repeat antibiotic prescription for LRTI compared to
non-smokers (OR 0.78, 95% CI 0.78–0.81, p < 0.001).
Ex-smokers were more likely to receive repeat antibio-
tics than non-smokers (OR 1.04, 95% CI 1.01–1.07,
p = 0.02). Ex-smokers were at significantly higher risk
of repeat antibiotic prescription compared to current
smokers (OR 1.34, 95% CI 1.29–1.39, p < 0.001). Not
using amoxicillin as index antibiotic was associated with
more repeat antibiotic prescriptions (OR 1.15, 95% CI
1.11–1.18, p < 0.001). Seven day index courses were
associated with more repeat prescriptions than both
shorter and longer courses (OR 0.93, 95% CI
0.90–0.96, p < 0.001; OR 0.86, 95% CI 0.79–0.94,
p = 0.001 respectively). Higher BMI was associated
with further prescriptions (mean 28.5 ± 6.3 vs
28.1 ± 6.7, MD −0.46, 95% CI −0.6 – −0.4, p < 0.001).
There was no difference gender (p = 0.08).
Figure 1 shows that most repeat antibiotic prescrip-
tions occurred following an index duration of 7 days.
The proportion of cases receiving further antibiotics
decreased with longer and shorter index duration.
Fewer repeat prescriptions occurred when amoxicillin
was used as index antibiotic.
Subgroup analysis for repeat LRTI code from 2011 to
2017
About 89,694 cases were included in this period. The
most commonly prescribed index duration was again
7 days (83.7%).The most frequently used index anti-
biotics were amoxicillin (70.3%), clarithromycin
(14.7%) and co-amoxiclav (4.8%).
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Men were less likely to receive further antibiotics (OR
0.93, p = 0.01, see Supplementary Table 2). Those receiv-
ing antibiotics were significantly older (mean age 60
versus 57 years, p < 0.001) with a higher BMI (29.0
versus 28.6, p < 0.001). Current smokers were less likely
to receive antibiotics (OR 0.81, 95% CI 0.76–0.87,
Table 1. Univariable analysis for repeat antibiotic prescription with LRTI code (total number 366,640).
Receiving second antibiotic course for LRTI
Analysed variable Yes No Calculation p value
Age (years) 57.5 ± 16.6 54.1 ± 17.7 MD −3.4 (95% CI −3.6 to −3.1) < 0.001
Smoking status
Non-smoker 8,528 (6.6%) 121,363 (93.4%) OR 1.00
Current smoker 5,135 (5.2%) 93,929 (94.8%) OR 0.78 (95% CI 0.75–0.81) < 0.001
Ex-smoker 7,208 (6.8%) 98,737 (93.2%) OR 1.04 (95% CI 1.01–1.07) 0.02
Missing n = 31,740
Index drug
Amoxicillin 13,905 (5.8%) 224,716 (94.2%) OR 1.00
Not amoxicillin 7,323 (6.6%) 103,339 (93.4%) OR 1.15 (95% CI 1.11–1.18) < 0.001
Missing n = 17,357
Index antibiotic duration
7 days 16,732 (6.2%) 254,769 (93.8%) OR 1.00
< 7 days 4,904 (5.8%) 80,188 (94.2%) OR 0.93 (95% CI 0.90–0.96) < 0.001
> 7 days 540 (5.4%) 9,507 (94.6%) OR 0.86 (95% CI 0.79–0.94) 0.001
BMI (kg/m2) 28.5 ± 6.3 28.1 ± 6.7 MD −0.46 (95% CI −0.6 to −0.4) < 0.001
Gender
Female 12,957 (6.1%) 199,185 (93.9%) 1.00 0.08
Male 9219 (6.0%) 145,279 (94.0%) OR 0.98 (95% CI 0.95–1.00)
(Mean ±SD or absolute number +row % where appropriate; SD: standard deviation; OR: odds ratio; 95% CI: 95% Confidence interval; MD: mean difference; p
value as per students T-test or Chi-Square)
Figure 1. Percentage of all prescriptions of specified index duration and index antibiotic receiving second antibiotic prescription for
LRTI (a) or any indication (b) within 14 days of index antibiotic prescription, by index duration and antibiotic group. (*p < 0.005 by
Chi-square test).
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p < 0.001) than non-smokers, ex-smokers more likely
than non-smokers (OR 1.05, 95% CI 0.99–1.11, p = 0.11)
and significantly more likely than current smokers (OR
1.29, 95% CI 1.20–1.38, p < 0.001). Not using amoxicillin
as index antibiotic retained a higher risk of repeat pre-
scription (OR 1.11, 95% CI 1.04–1.17, p < 0.001). In
contrast to the overall study findings shorter durations
were now associated with a higher risk of repeat pre-
scription than 7 day courses (OR 1.12, 95% CI 1.05–1.20,
p = 0.001). Longer durations maintained their lower risk
of repeat antibiotics (OR 0.85, 95% CI 0.71–1.01,
p = 0.06).
Further antibiotic prescription for any indication
When considering all antibiotic prescriptions within
14 days of index prescription (41,227 cases) clarithro-
mycin, amoxicillin and doxycycline were used most
commonly as second line agents (20.5%, 17.0%
and 13.7%).
Those receiving further courses were significantly
older (mean 57.2 vs 54.0 years, p < 0.001) with a sig-
nificantly higher BMI (mean 28.5 vs 28.1, p < 0.001, see
Supplementary Table 3). Men were significantly less
likely to receive antibiotics than women (OR 0.93, 95%
CI 0.91–0.95, p < 0.001). Current smokers were less
likely, ex-smokers more likely to receive antibiotics
than non-smokers (OR 0.79, 95% CI 0.77–0.82,
p < 0.001 and OR 1.04, 95% CI 1.01–1.07, p = 0.002
respectively). Ex-smokers were significantly more likely
to receive further antibiotics than current smokers (OR
1.31, 95% CI 1.28–1.35, p < 0.001). Not using amoxicillin
as index drug was associated with higher risk of repeat
antibiotics (OR 1.18, 95% CI 1.16–1.21, p < 0.001; see
Figure 1(b)). Shorter index courses were associated with
fewer repeat prescriptions than 7-day index courses (OR
0.94, 95% CI 0.91–0.96, p < 0.001). There was no sig-
nificant difference between longer and 7 day courses
(OR 0.94, 95% CI 0.88–1.00, p = 0.06).
Discussion
We present a report of antibiotic prescribing for LRTI in
over 525 primary care practices in the United Kingdom
over 33 years. More than 365,000 truly representative,
index prescriptions were analysed and more than 1 in 20
received two antibiotic courses for LRTI within 14 days.
Our hypothesis-generating findings support the wide-
spread use of amoxicillin as index drug and suggest that
initial courses shorter than seven days could potentially be
effective, as they were associated with a lower risk of repeat
prescriptions. These findings should be confirmed in inter-
ventional studies.
A key output from this study is a description of the
frequency of and variation in prescribing practice for
LRTI in primary care. Repeat antibiotic prescribing was
common and in discrepancy to UK guidelines: the
National Institute for Health and Care Excellence does
not recommend routine antibiotic prescription for those
presenting with likely self-limiting illnesses, including
acute bronchitis, in primary care since in the majority of
cases no pathogen or only respiratory viruses can be
identified [8]. Yet 6.2% of our population even received
two antibiotic courses for LRTI within two weeks.
Treatment failure rates of 20% have been described
previously but these included prescriptions for pneumo-
nia and further antibiotics for all indications [9]. We
present more specific data for LRTI, which can assist to
plan future work. Most cases had only one index pre-
scription; however, subgroup analysis of those with
more index prescriptions showed no significant differ-
ences to the presented findings.
Our findings were inconclusive regarding duration,
highlighting the need for interventional research.
Overall, shorter and longer courses than seven days
seemed to be more successful at reducing the need
for further antibiotics for LRTI. Shorter courses also
had a lower risk for all repeat indications. However,
shorter courses were associated with increased repeat
prescriptions in the subgroup analysis from 2011 to
2017, whilst longer courses maintained their superior-
ity over seven day courses. Yet for all indications there
was no difference between longer and seven day
courses. With our data we are unable to establish
whether this reflects changes in pathogens and disease
or changes in presenting and prescribing behaviour by
patients and clinicians. We did not have access to
adverse effect data, which would be important for any
future studies. A recent meta-analysis found an asso-
ciation of adverse effects and longer antibiotic duration
in COPD patients [10].
Repeat prescriptions were more common in older sub-
jects, those with a higher BMI or previous smoking history.
These findings appear to be clinically relevant and plausi-
ble as, for example older patients are at higher risk of
adverse outcomes from community acquired pneumonia
[11]. Patients with previous smoking history are at risk of
abnormal lung architecture, COPD and hence atypical
bacterial infections [12,13]. Higher BMI may impair clear-
ing of secretions but the mean difference in BMI was only
0.4 between groups which is unlikely to relate to clinical
significance. Further work should be undertaken as these
groups may have different needs for drugs and durations
for LRTI due to co-morbidities and different lung archi-
tecture. Amoxicillin treats Streptococcus pneumoniae, the
most common bacterial cause of LRTI, hence our finding
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of fewer repeat prescriptions after initial amoxicillin ther-
apy could be clinically plausible [12]. Whilst the effect sizes
were small, LRTI are very common [9]. Hence even small
differences of less than 1% could theoretically result in
meaningful differences in antibiotic prescriptions due to
the size of the population, if they were true. It may be
worth exploring this in the future.
Current smokers seemed to have a significantly
reduced risk of repeat prescriptions (OR 0.78, 95% CI
0.75–0.81). Doctors may attribute cough in a current
smoker to the smoking and hence not prescribe antibio-
tics. This is in contrast to retrospective European data
where current smoking was an independent risk factor
for antibiotic prescription in primary care patients pre-
senting with cough and the increased risk of community
acquired pneumonia and death of pneumococcal disease
in smokers [14,15]. Yet the cough study demonstrated no
improved recovery with antibiotics and subgroup analy-
sis of a multi-centre randomised, placebo-controlled trial
of amoxicillin versus placebo in LRTI showed no clini-
cally meaningful advantage of antibiotic treatment, sup-
porting our described UK findings [16].
We analysed electronic health records. There is a
drive to use more routinely collected data, particu-
larly in primary care research, for example from the
National Institute of Health Research, and high-
lighted by recent successes such as the Salford Lung
Study, to reduce burden on patients, bias and
approximate real-world practice [17,18]. However,
the reliance on primary care data is also this study’s
major limitation – specifically the 49% of cases for
which no index antibiotic duration was documented.
The excluded cases had a lot of missing data (see
Supplementary Table 4). The missing data had fewer
non-smokers (8.8%) but also more missing smoking
data (26%). It is unclear whether this represents a
true difference in prevalence of non-smoking or fail-
ure to code an absence of disease. We were unable to
comment on the repeat prescriptions in the non-
included group due to too much missing data. One
may suspect that documentation improved over time
with advancing information technology, however,
from 2011 to 2017 there were 206,455 cases in the
database – and only 89,694 with a documented index
duration (43%). More integrated healthcare technol-
ogies need to improve this in the future.
Other limitations include lack of information on
other healthcare contacts or signs of infection and on
other confounders, for example non-respiratory co-
morbidities, allergies, prior antibiotic use, unattainabil-
ity of total number of LRTI in the study period and
inability to distinguish appropriate from inappropriate
prescribing. Yet treatment decisions are often made
independent of these, for example initial clinical sever-
ity scores and clinical response to therapy were not
related to duration of antibiotic therapy in adults
admitted with community acquired pneumonia [19].
Variations in clinical presentation did not explain the
large discrepancies in antibiotic prescribing for acute
cough in a cross-sectional study of 14 European coun-
tries [20]. Repeat prescriptions could have been issued
due to genuine anti-microbial failure, but also due to
drug failure caused by side effects or incorrect diag-
noses. Better data is needed to distinguish these.
Nevertheless, we present a hypothesis-generating real-
world picture of the prescribing patterns of antibiotics for
LRTI over 33 years in 7% of all UK primary care practices,
analysing over 365,000 cases. With evidence on effective
antibiotic treatment currently lacking it is paramount to
have a historical, pragmatic perspective as a basis to
design safe interventional studies in the future.
Conclusion
Antibiotics were prescribed for LRTI in people without
chronic chest conditions. There was variation in practice
and apparent deviation from guidelines. Amoxicillin as
index drug seemed more successful in avoiding repeat
antibiotic prescriptions than other agents, supporting the
demonstrated current prescribing practice. The results
for optimal antibiotic duration were less clear, but sug-
gested that shorter index durations may be appropriate
for LRTI. This pragmatic study has implications for
further work around guideline implementation, antimi-
crobial resistance strategies, and interventional studies of
antibiotic duration.
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